VectivBio Holding AG
North American company
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. The product candidate is apraglutide, which is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which is developed as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.
Latest VECT News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News